Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
IL-12/23 inhibitors
5 evidence topics · 5 sources
Biologics guideline: ustekinumab recommendation
Ustekinumab: FDA-approved indication and weight-based dosage every 12 weeks
Ustekinumab: Ps STUDY 1 and Ps STUDY 2 outcomes at week 12
| Outcome at Week 12, n (%) | Ps STUDY 1 placebo (N=255) | Ps STUDY 1 STELARA 45 mg (N=255) | Ps STUDY 1 STELARA 90 mg (N=256) | Ps STUDY 2 placebo (N=410) | Ps STUDY 2 STELARA 45 mg (N=409) | Ps STUDY 2 STELARA 90 mg (N=411) |
|---|---|---|---|---|---|---|
| PASI 75 response | “8 (3%)” | “171 (67%)” | “170 (66%)” | “15 (4%)” | “273 (67%)” | “311 (76%)” |
| PGA of cleared or minimal | “10 (4%)” | “151 (59%)” | “156 (61%)” | “18 (4%)” | “277 (68%)” | “300 (73%)” |
Decision aid: ustekinumab
| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
|---|---|---|
| Ustekinumab | “34%” | “84–86% chance” |
Network meta-analysis: ustekinumab compared with other biologics and oral agents
“Anti‐IL17 class had a better chance of reaching PASI 90 using SUCRA (versus placebo: RR 25.58, 95% CI 21.64 to 30.23; SUCRA = 99.2), followed by anti‐IL23 (versus placebo: RR 22.25, 95% CI 18.70 to 26.48; SUCRA = 86.4), anti‐IL12/23 (versus placebo: RR 17.71, 95% CI 14.68 to 21.36; SUCRA = 71.5), and anti‐TNF‐alpha (versus placebo: RR 13.33, 95% CI 11.21 to 15.85; SUCRA = 57.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ustekinumab was superior to certolizumab (RR 1.43, 95% CI 1.07 to 1.92).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secukinumab, ixekizumab, brodalumab, risankizumab, and bimekizumab were more effective than ustekinumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adalimumab, tildrakizumab, and ustekinumab were superior to etanercept, deucravacitinib, and apremilast.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For reaching PASI 90 at 52 weeks, risankizumab was more effective than ustekinumab (RR 1.73, 95% CI 1.46 to 2.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
|---|---|---|---|
| Ustekinumab, 45 mg ≤100 kg, 90 mg >100 kg | “69.7 (66.3-73.1)”View highlighted excerpt for this quote | “43.9 (40.2-47.9)”View highlighted excerpt for this quote | “16.7 (14.4-19.3)”View highlighted excerpt for this quote |